Rectal Cancer News

CancerConnect rectal cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of rectal cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of rectal cancer treatment and survivorship.

Share

Rectal Cancer News


Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch... Continue Reading

Innovative Colorectal Cancer Screening Methods for Remote Areas (June 16, 2016)

Colorectal cancer is the second-leading cause of cancer-related death in the United States, despite the fact that more than half of these deaths are avoidable with regular screenings. In fact, with screening,... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to... Continue Reading

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (May 11, 2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor... Continue Reading

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (May 9, 2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent... Continue Reading

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of... Continue Reading

Pass It On: It’s Colorectal Cancer Awareness Month (March 3, 2016)

The colon and rectum are parts of the digestive system, and make up the large intestine. Most of the large intestine is made up of the colon, a muscular tube about five feet long, with the rectum making... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The... Continue Reading

Colorectal Cancer: Year in Review (February 3, 2016)

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has... Continue Reading

More Rectal Cancer News

Latest Rectal Cancer News By Stage


Screening and Prevention

Innovative Colorectal Cancer Screening Methods for Remote Areas (June 16, 2016)

Colorectal cancer is the second-leading cause of cancer-related death in the United States, despite the fact that more than half of these deaths are avoidable with regular screenings. In fact, with screening, patients can prevent colon cancer from ever... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to engage with a hereditary cancers expert, Kimberly... Continue Reading

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

Pass It On: It’s Colorectal Cancer Awareness Month (March 3, 2016)

The colon and rectum are parts of the digestive system, and make up the large intestine. Most of the large intestine is made up of the colon, a muscular tube about five feet long, with the rectum making up the final 6 inches of the digestive tract. Most... Continue Reading

More Screening and Prevention

Stages I-III

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for patients with advanced rectal cancer. The study... Continue Reading

Preoperative Arterial Chemotherapy Appears Superior to Post-operative Chemotherapy in the Management of Early Stage Colorectal Cancer (March 18, 2015)

CancerConnect News: Doctors from China have reported at the annual Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology in San Francisco that giving preoperative chemotherapy directly into the common hepatic artery... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource and support group. Click on one of the links... Continue Reading

FOLFOX Improves Disease-Free Survival in Stage II and III Rectal Cancer Patients (June 11, 2014)

Researchers at the University of Ulsan College of Medicine in South Korea reported that treatment with the FOLFOX chemotherapy regimen in rectal cancer patients improved 3-year disease-free survival over a standard chemotherapy of 5-FU/leucovorin. The... Continue Reading

More Stages I-III

Stage IV

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for patients with advanced rectal cancer. The study... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (August 24, 2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (June 23, 2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University... Continue Reading

More Stage IV

Recurrent/Relapsed

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for patients with advanced rectal cancer. The study... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced... Continue Reading

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer (March 17, 2015)

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (February 19, 2015)

CancerConnect News: The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According... Continue Reading

More Recurrent/Relapsed

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS